Key clinical point: Synthesis of the spike protein provides a tool for vaccine development, as well as a potential therapeutic target.
Major finding: The 2019-nCoV spike protein, despite high sequence homology, did not react to monoclonal antibodies developed for the SARS-CoV-1 spike protein.
Study details: Using gene sequence information, researchers synthesized the 2019-nCoV spike protein trimer and determined a 3.5-Angstrom-resolution cryo-EM structure.
Disclosures: This work was supported in part by an National Institutes of Health/National Institute of Allergy and Infectious Diseases grant and by intramural funding from the National Institute of Allergy and Infectious Diseases. Four authors are inventors on US patent application No. 62/412,703 (Prefusion Coronavirus Spike Proteins and Their Use) and all are inventors on US patent application No. 62/972,886 (2019-nCoV Vaccine).
Wrapp D et al. Science. 2020 Feb 19. doi: 10.1126/science.abb2507.